Stocktoria

KIORA PHARMACEUTICALS INC KPRX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-02-13 · LEI

KIORA PHARMACEUTICALS INC statistics & valuation

P / B0.7×
Return on capital-62.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
-656.30% -68104.80% 28.20% 2016201720182019202020212022202320242025
Return on equity (%)
-175.00% -121.00% -107.20% -83.20% -94.50% -119.10% -204.80% 14.00% -67.20% 2016201720182019202020212022202320242025
Shares outstanding
10.1M 17.3M 3.0M 4.1M 5.6M 316599 1.8M 856182 4.1M 4.2M 2016201720182019202020212022202320242025
Net debt ($)
-$3.8M -$907487 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-92.40% -75.70% -70.20% -53.40% -68.40% -72.70% -91.30% 9.90% -44.70% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-1257.10% -1596.40% -657.50% -303.60% -60844.60% 53.40% 2016201720182019202020212022202320242025
Debt / equity (×)
0.00× 0.03× 2016201720182019202020212022202320242025
EPS ($)
-$1.77 -$57.12 -$18.55 -$24.25 $0.87 -$2.64 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating margin28.2%-68104.8%-656.3%
Net margin22.4%-67102.9%-264.2%-654.2%-3243.5%
FCF margin53.4%-60844.6%-303.6%-657.5%-1596.4%-1257.1%
Return on assets-44.7%9.9%-91.3%-72.7%-68.4%-53.4%-70.2%-75.7%-92.4%
Return on equity-67.2%14.0%-204.8%-119.1%-94.5%-83.2%-107.2%-121.0%-175.0%
Debt / equity0.03×0.00×
Current ratio5.994.942.902.355.590.973.062.190.570.57

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.